Winlevi (clascoterone) works differently from every other acne treatment on the market because it’s the first topical medication to block androgen receptors in your skin—a completely novel mechanism that the FDA approved for the first time in nearly 40 years. While benzoyl peroxide kills bacteria and retinoids increase cell turnover, Winlevi attacks acne at its hormonal root by preventing dihydrotestosterone from triggering sebum production and inflammation in your skin cells.
For someone with hormonally-driven acne who hasn’t responded to standard treatments, this represents a genuinely different approach, not just another variation on existing technology. The difference matters because Winlevi doesn’t require the systemic hormone manipulation that oral antiandrogen medications demand. This article breaks down exactly how Winlevi’s mechanism sets it apart, what the clinical trial data actually shows about its effectiveness, why its safety profile is unique, and how it fits into treatment decisions for different types of acne.
Table of Contents
- How Does Winlevi’s Androgen-Blocking Mechanism Differ from Traditional Acne Treatments?
- What Do the Phase 3 Clinical Trials Actually Show About Winlevi’s Effectiveness?
- How Does Winlevi’s Safety Profile Differ from Oral Antiandrogen Medications?
- Which Patients Benefit Most from Winlevi Compared to Benzoyl Peroxide or Retinoids?
- What Are the Limitations and Potential Drawbacks of Winlevi?
- How Does Winlevi Fit into a Treatment Timeline and Combination Approach?
- What’s the Future of Topical Androgen Receptor Inhibitors in Acne Treatment?
- Conclusion
How Does Winlevi’s Androgen-Blocking Mechanism Differ from Traditional Acne Treatments?
Winlevi’s fundamental difference lies in its target. Benzoyl peroxide works by generating free radicals that kill *Cutibacterium acnes* (formerly called *Propionibacterium acnes*), the bacteria involved in acne. Retinoids work by increasing skin cell turnover and reducing sebum plugging. Topical antibiotics reduce bacterial populations. All of these address acne from different angles, but none of them block the hormonal signals that make your skin produce excess sebum in the first place. Winlevi does exactly that—it competes with dihydrotestosterone (DHT) for androgen receptors in the pilosebaceous unit (the hair follicle and sebaceous gland together), essentially blocking the hormone’s ability to trigger acne.
This matters because hormonal acne exists on a spectrum. Some acne is purely bacterial, some is purely inflammatory, and some is fundamentally driven by hormone sensitivity in the skin’s oil glands. People who get acne flare-ups around their menstrual cycle, or whose acne has a distinctly oily quality that other treatments don’t adequately address, are often dealing with hormone-sensitive acne. For those patients, using benzoyl peroxide or a retinoid is like trying to treat a fire by removing some of the wood while someone’s still pouring gasoline on it. Winlevi removes the gasoline. The FDA approved Winlevi on August 26, 2020, marking the first new acne mechanism in nearly 40 years. Clinical testing in 1,440 patients aged 9 and older showed that clascoterone reduced noninflammatory lesions by an average of 19.4 compared to 10.8–13.0 with placebo—a meaningful gap that reflects how effectively blocking androgen signaling addresses this specific type of acne.
What Do the Phase 3 Clinical Trials Actually Show About Winlevi’s Effectiveness?
The two randomized Phase 3 trials that led to FDA approval studied 1,440 patients with moderate acne over 12 weeks, comparing clascoterone cream to a placebo vehicle. The results broke down into three categories: noninflammatory lesions (comedones), inflammatory lesions (pimples and cysts), and overall treatment success. Clascoterone reduced inflammatory lesions by 19.3–20.0 compared to 12.6–15.5 with placebo—a reduction that’s clinically meaningful because inflammatory lesions are typically the ones that cause the most distress and scarring risk. What’s more telling is the “clear skin” endpoint. In dermatology, physicians measure success using the IGA (Investigator’s Global Assessment) scale, where a score of 1 or lower means your acne is essentially cleared. About 20% of clascoterone patients achieved this threshold compared to only 6–9% in the placebo group.
That gap reveals something important: Winlevi doesn’t just improve acne; it actually clears it entirely for a meaningful percentage of users. However, it’s worth noting that “meaningful improvement” still leaves 80% of patients with some residual acne, suggesting that combination therapy (Winlevi plus a retinoid, for instance) might outperform monotherapy for many people. Total lesion reduction—combining inflammatory and noninflammatory—showed a 38% reduction with clascoterone versus 22–28% with placebo. This is a substantial advantage, but the 12-week timeframe is important context. Acne treatment often takes 8–12 weeks to show results because the skin has to cycle through its natural processes. Patients who don’t see improvement within that window may not be ideal candidates for Winlevi monotherapy.
How Does Winlevi’s Safety Profile Differ from Oral Antiandrogen Medications?
One of the most critical differences between Winlevi and systemic acne treatments like spironolactone (an oral medication used off-label for hormonal acne) is that Winlevi acts entirely locally in the skin. Spironolactone works by blocking androgen receptors throughout your entire body, which is why it can trigger systemic side effects: dizziness, low blood pressure, electrolyte imbalances, and in rare cases, gynecomastia (breast tissue growth in males). These side effects are serious enough that dermatologists must monitor blood pressure and electrolytes in patients taking spironolactone long-term. Winlevi produces no such systemic effects because the medication never enters the bloodstream in meaningful amounts. The most common adverse events in the clinical trials were localized skin reactions: erythema (redness), itching, burning, and peeling in 7–12% of patients.
These are exactly what you’d expect from a topical treatment and are indistinguishable from the irritation caused by benzoyl peroxide or tretinoin. Importantly, these effects were mild, meaning they didn’t cause patients to stop treatment. This makes Winlevi uniquely valuable for patients—particularly males—who experienced hormonal acne that responded to oral antiandrogens but couldn’t tolerate the systemic side effects. There is, however, a practical limitation: Winlevi’s localized action means it won’t help with hormonal acne’s systemic drivers. Someone with significant hormonal acne tied to underlying polycystic ovary syndrome (PCOS) or other endocrine conditions might need systemic treatment in addition to topical therapy. Winlevi addresses the skin’s hormonal sensitivity but doesn’t correct underlying hormonal imbalances.
Which Patients Benefit Most from Winlevi Compared to Benzoyl Peroxide or Retinoids?
The ideal Winlevi candidate is someone whose acne has a clear hormonal component but who either can’t or won’t use systemic medications. For example, a 16-year-old male with oily skin and breakouts concentrated on his face and chest—areas rich in androgen-sensitive sebaceous glands—is a good fit. So is a woman with menstrual-cycle-related acne who tried spironolactone but experienced side effects. The FDA label approves Winlevi for ages 12 and up, in both males and females, which reflects this broad applicability. Where the comparison gets interesting is against combination therapy.
A common dermatology approach for moderate hormonal acne is benzoyl peroxide plus a retinoid, which addresses bacterial overgrowth and follicular plugging while improving skin turnover. This combination works very well for many people, but it doesn’t directly address the hormonal signal driving excess sebum. Adding Winlevi to that regimen—or using Winlevi alone if someone is retinoid-intolerant or can’t tolerate benzoyl peroxide’s drying effects—offers a different strategic angle. However, Winlevi isn’t a replacement for other treatments in most cases; it’s an alternative or an addition. One practical consideration: retinoids take 3–6 months to reach full effectiveness, while Winlevi’s clinical trials showed meaningful results within 12 weeks. For someone who needs faster improvement, Winlevi might be the better starting point, though combining it with a gentler retinoid after initial improvement could yield even better long-term results.
What Are the Limitations and Potential Drawbacks of Winlevi?
Winlevi isn’t a cure-all, and understanding its limitations is crucial for realistic expectations. First, it doesn’t address bacterial overgrowth—the exact problem that benzoyl peroxide solves. If someone’s acne is primarily driven by *C. acnes* proliferation (for instance, acne that flares up in warm, humid environments or after occlusive clothing), Winlevi alone may underperform. Second, it provides no exfoliating benefit, unlike retinoids, so it won’t help with texture or clogged pores that result from slow skin cell turnover. Cost and access present another real barrier.
Winlevi is a brand-name topical, and insurance coverage varies widely. Unlike generic benzoyl peroxide or tretinoin, it’s often significantly more expensive out-of-pocket. For someone without robust insurance, this cost barrier might outweigh the mechanism advantage. Additionally, while the safety profile is excellent, the clinical trials involved only 12 weeks of treatment. Long-term safety data beyond 12 weeks is limited, though post-market surveillance hasn’t identified concerns. If someone needs to use Winlevi for years (which is common with acne treatment), the long-term picture is still being written. Finally, Winlevi works best as part of a comprehensive regimen rather than in isolation—using it without addressing lifestyle factors like diet, stress, and skincare hygiene will likely underperform.
How Does Winlevi Fit into a Treatment Timeline and Combination Approach?
Most dermatologists approach Winlevi as either a standalone therapy for mild-to-moderate hormonal acne or as part of a stepwise combination regimen. A typical timeline might look like this: Week 0–2, start Winlevi and a gentle cleanser, assess tolerability. Week 2–6, maintain Winlevi and introduce a low-dose retinoid (like 0.025% tretinoin or adapalene). Week 6–12, continue both, adjusting frequency based on irritation.
By week 12, the dermatologist can assess whether the combination is working or if adjustments are needed. This approach leverages Winlevi’s androgen-blocking activity with retinoid’s cell-turnover benefits, creating a synergistic effect. The retinoid addresses follicular plugging and skin texture while Winlevi reduces the hormonal drive behind excess sebum. Someone following this pathway might expect to see meaningful improvement by 8–10 weeks, with continued refinement over months.
What’s the Future of Topical Androgen Receptor Inhibitors in Acne Treatment?
Winlevi’s approval was groundbreaking because it proved that blocking androgen signaling topically could be both effective and safe for acne. However, it’s not the endpoint of research in this area. Dermatologists and pharmaceutical researchers are exploring whether combining Winlevi with other novel mechanisms—such as sebum-regulating compounds or anti-inflammatory agents—could yield even better results.
There’s also ongoing investigation into whether younger patients (ages 9–11) with hormonally-driven acne represent an untapped population that could benefit from this mechanism. The broader implication is that acne treatment is moving away from one-size-fits-all approaches toward mechanism-matched therapy: hormonal acne gets androgen inhibition, bacterial acne gets antimicrobials, and texture problems get retinoids. As this personalization continues, topical androgen inhibitors will likely become a standard part of the dermatologist’s toolkit, particularly for patients who don’t fit neatly into traditional treatment categories.
Conclusion
Winlevi (clascoterone) is fundamentally different from other acne treatments because it’s the first topical medication to block androgen receptors in skin, addressing the hormonal root of acne rather than just its symptoms. The Phase 3 clinical trials demonstrated meaningful efficacy—38% total lesion reduction, 20% clear skin rates—with an excellent safety profile showing only mild, localized side effects and no systemic hormone-related complications.
For patients with hormonal acne who struggled with oral antiandrogens or who simply haven’t responded to benzoyl peroxide and retinoids, Winlevi represents a genuinely novel option. The key to using Winlevi effectively is understanding it’s not a replacement for existing treatments but rather a complementary approach best combined with other therapies and used as part of a comprehensive acne management plan. If your acne has a hormonal component, your dermatologist is struggling to manage it with traditional treatments, or you experienced side effects from systemic medications, asking about Winlevi is worth the conversation.
